Kite presents ZUMA-1 trial data at ASH meeting

Kite Pharma recently presented the results of its ZUMA-1 clinical trial involving axicabtagene ciloleucel (KTE-C19) at the American Society of Hematology (ASH) 58th Annual Meeting.
The trial dealt with the treatment of patients who have chemorefractory aggressive non-Hodgkin lymphoma.
"The vast majority of patients enrolled in ZUMA-1 are unable to undergo autologous stem cell transplant due to chemorefractory disease. This group has a dire need for more effective therapies,” Dr. Jeff Wiezorek, senior vice president of clinical development, said. “We are encouraged by the high rate of complete remissions in this group and look forward to presenting longer follow-up at the primary analysis in the first quarter 2017. We are grateful to the patients and investigators who have made this important study possible.”
There were 111 patients who have diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or transformed follicular lymphoma enrolled in the ZUMA-1 trial. It was required of the enrolled patients to have chemorefractory disease, which is defined as having a progressive or stable disease as the best possible response to the last therapy received or having their disease profess less than a year after receiving autologous stem cell transplant.